Vandetanib, an approved EGFR inhibitor for medullary thyroid cancer, targets EGFR, VEGFR, and RET, offering broad efficacy, but is limited by adverse effects like diarrhea, rash, nausea, hypertension, and QT prolongation. This evidence concerns the gene KDR and medullary thyroid gland carcinoma.